A novel coronavirus designated as SARS-CoV-2 in February 2020 by World Health organization (WHO) was identified as main cause of SARS like pneumonia cases in Wuhan city in Hubei Province of China at the end of 2019. This been recently declared as Global Pandemic by WHO. There is a global emergency to identify potential drugs to treat the SARS-CoV-2. Currently, there is no specific treatment against the new virus. There is an emergency to identifying potential antiviral agents to combat the disease is urgently needed. An effective and quick approach is to test existing antiviral drugs against. Patients affected with Novel coronavirus had shown severe respiratory inflammatory burst which includes sever cytokine and lymphocyte over responses.

References

1. Philippe A Grange., et al. “Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kB and MAPK pathways”. Journal of Dermatological Science2 (2009): 106-112.
2. Raphael G., et al. “Neutrophil recruitment is inhibited by Nicotinamide in experimental pleurisy in mice”. European Journal of Pharmacology1-3 (2012): 198-204.
3. G Monfrecola., et al. “Nicotinamide down regulates gene expression of interleukin‐6, interleukin‐10, monocyte chemoattractant protein‐1, and tumour necrosis factor‐α gene expression in HaCaT keratinocytes after ultraviolet B irradiation”. Clinical and Experimental Dermatology 2 (2013): 185-188.
4. Rafał Biedron., et al. “1-Methylnicotinamide and Nicotinamide: two related anti-inflammatory agents that differentially affect the functions of activated macrophages”. Archivum Immunologiae et Therapiae Experimentalis 2 (2008): 127-134.

Citation

Citation: Hemanth Kumar Manikyam and Sunil K Joshi. “Nicotinamide, Folic Acid and Derivatives as Potent Inhibitors of Inflammatory Factors against Novel Corona Virus Infection". Acta Scientific Pharmacology 1.5 (2020): 04.

Copyright

Copyright: © 2020 Hemanth Kumar Manikyam and Sunil K Joshi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.